Disclaimer: Due to limited expertise, errors are inevitable, and some information may not be the most up-to-date. Comments pointing out any issues are welcome. This article is only an introduction to medical and health-related drugs and does not recommend any treatment plans (if involved). This article does not constitute any investment advice.
On May 13, SCG SCIENCE (DALIAN) CO., LTD presented the preclinical data of its next-generation human papillomavirus (HPV)-specific T-cell receptor (TCR) engineered T-cell therapy - SCG142, in an oral presentation at the 27th Annual American Society of Gene and Cell Therapy Meeting held in Baltimore, USA. The research data demonstrated that the new generation of SCG142 TCR-T cell therapy significantly enhances T-cell proliferation and tumor suppression, showing excellent anti-tumor activity and good safety in HPV-related tumor models.
According to the disclosed content, compared with traditional TCR-T cell therapy, the next-generation TCR-T cell therapy enhanced by a chimeric switch receptor demonstrated in both in vitro and in vivo models that SCG142 can dual-activate CD8+ and CD4+ TCR T cells to exert potent anti-tumor activity in an inhibitory tumor microenvironment without relying on CD8 co-receptor signaling. It also promotes the long-term persistence of memory T cells, playing a key role in achieving the durable therapeutic effects of immune cell therapy. Additionally, the high-affinity characteristic of SCG142 allows it to simultaneously recognize various HPV-related tumors, including cervical cancers associated with HPV-16 and HPV-52 genotypes, significantly increasing patient population coverage.Dr. Ke Zhang, Chief Scientific Officer of SCG SCIENCE (DALIAN) CO., LTDStated: "SCG142 represents a completely new and differentiated next-generation TCR-T cell therapy. By combining naturally high-affinity HPV-specific TCR T cells with a chimeric switch receptor, we enable T cells to overcome the suppressive tumor microenvironment while further enhancing the proliferation and tumor-killing effects of CD8+ and CD4+ TCR T cells, which is crucial for the effective treatment of solid tumors. Leveraging its exclusive, globally leading technology platform GianTCRTM, SCG SCIENCE has successfully screened and isolated fully natural TCRs with high affinity, eliminating the need for artificial affinity maturation and avoiding the risk of off-target toxicity. This approach also achieves effective antiviral and antitumor dual efficacy in infection-related solid tumors. Following the significant efficacy and benefits demonstrated by SCG101, SCG SCIENCE’s first TCR-T cell therapy targeting hepatitis B virus (HBV) in treating liver cancer patients, we are highly optimistic that this next-generation TCR-T cell therapy will exhibit stronger efficacy and lower costs in new therapeutic areas, bringing benefits to more patients with cervical cancer and other tumors."About Human Papillomavirus and CancerHuman Papillomavirus (HPV) is the most common sexually transmitted infection, and nearly all sexually active individuals are infected with HPV. HPV infection can lead to cellular changes, forming precancerous lesions in the cervix, vagina, vulva, anus, or throat, which may induce various malignant tumors such as cervical cancer, vaginal cancer, vulvar cancer, anal cancer, and oropharyngeal cancer. Nearly 100% of cervical cancer cases are caused by HPV infection1,2. In 2020, there were 604,000 new cases of cervical cancer globally and approximately 342,000 deaths, making it one of the most common malignant tumors among women worldwide3.SCG SCIENCE (DALIAN) CO., LTD is a leading biotechnology company focused on developing novel immunotherapies for infections and their associated cancers. The company is developing a broad and unique range of TCR-T cell therapies targeting the most common cancer-causing infections: Helicobacter pylori, human papillomavirus, and hepatitis B, with the goal of preventing and curing infections and their related cancers. Headquartered in Singapore, with its R&D center located at the IZB Innovation Center in Munich, Germany, the company leverages regional advantages from Singapore, China, and Germany, covering the complete industry value chain from innovative drug research and development, manufacturing, clinical trials, to commercialization.Source of the Article: SCG SCIENCE
